A programmable, cell-agnostic DNA nano-technology platform for CRISPR gene editing
A programmable, cell-agnostic DNA nano-technology platform for CRISPR gene editing
批准号:
EP/V048058/1
负责人:
Lorenzo Di Michele
金额:
$25.69万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2021
资助国家:
英国
项目状态:
已结题
起止时间:
2021 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
CRISPR-Cas9 gene editing has warranted its developers the 2020 Nobel Prize for Chemistry, in view of the massive impact that this technology is having on biological, biotechnological and medical research. In particular CRISPR gene editing is central to next generation cell-based therapies to treat cancer and other diseases, in which some of the patient's cells are extracted, genetically modified to fulfil specific functions, and then re-injected into the patient. This process is however time consuming and very costly, limiting the diffusion of these potentially life-saving therapies. One of the reasons behind the prohibitive costs is the low efficiency with which one can deliver to the cells the biological machinery required to perform CRISPR gene editing, both at scale and without excessive toxicity (leading to cell death).In this project, we will develop a novel and alternative approach to delivering CRISPR machinery to mammalian cells in vitro. Our approach will rely on specifically designed vectors, which we dub Editosomes. These are microscopic enclosures constructed from lipid membranes, similar to cell membranes, and containing large quantities of the CRISPR machinery.For Editosomes to deliver the machinery to the target cells the two would have to fuse. We will induce fusion by decorating both Editosomes and the target cells with artificial "fusogenic" nanomachines, that by binding to each other bring the cell and Editosome membranes to within a very short distance, ultimately making them merge. The fusogenic nanostructures will be constructed from synthetic DNA molecules, which are particularly suitable for engineering nanodevices in view of the very high selectivity and programmability of the base-pairing interactions.We envisage that Editosome technology will have a direct and profound impact on our ability to perform high-throughput, efficient, CRISPR gene editing in vivo, and thus on the accessibility and economic sustainability of the therapeutic technologies that rely on it.Additionally, we will clarify fundamental aspects of the (bio)physics underling lipid membrane stability, fusion, and the ability of DNA nanostructures to modulate them.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1039/d2sm00863g
发表时间:
2022-09-28
期刊:
Soft matter
影响因子:
3.4
作者:
[]
通讯作者:
2022BBSRC-NSF/BIO: Self-replicating synthetic cells programmed by RNA
-
批准号:BB/Y000196/1
-
项目类别:Research Grant
-
资助金额:$56.15万
-
财政年份:2024
-
负责人:Lorenzo Di Michele
-
依托单位:
EPSRC New Horizons 2021: Engineering synthetic synapses between artificial and biological cells.
-
批准号:EP/X018903/1
-
项目类别:Research Grant
-
资助金额:$25.78万
-
财政年份:2023
-
负责人:Lorenzo Di Michele
-
依托单位:
Japan_IPAP - Top-down meets bottom-up: Designer membrane-less organelles from condensation of synthetic RNA nanostructure
-
批准号:BB/X012557/1
-
项目类别:Research Grant
-
资助金额:$19.27万
-
财政年份:2023
-
负责人:Lorenzo Di Michele
-
依托单位:
国内基金
海外基金
登录
查看更多内容
全细胞疫苗Cell@MnO2的乳腺癌术后免疫响应监测与放射免疫治疗研究
-
批准号:QN25H220002
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:顾媛
-
依托单位:
染色体外环状DNA以cell-in-cell途径促进基因横向传递和扩增的研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:15.0万元
-
批准年份:2024
-
负责人:王锐智
-
依托单位:
GMFG/F-actin/cell adhesion 轴驱动 EHT 在造
血干细胞生成中的作用及机制研究
-
批准号:TGY24H080011
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:李鸿鹄
-
依托单位:
糖尿病ED中成纤维细胞衰老调控内皮细胞线粒体稳态失衡的机制研究
-
批准号:82371634
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:赵福军
-
依托单位:
基于In-cell NMR策略对“舟楫之剂”桔梗中引经药效物质的快速发现研究
-
批准号:82305053
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:王丽明
-
依托单位:
配子生成素GGN不同位点突变损伤分子伴侣BIP及HSP90B1功能导致精子形成障碍的发病机理
-
批准号:82371616
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:姚晨成
-
依托单位:
骨髓ISG+NAMPT+中性粒细胞介导抗磷脂综合征B细胞异常活化的机制研究
-
批准号:82371799
-
项目类别:面上项目
-
资助金额:47.00万元
-
批准年份:2023
-
负责人:杨程德
-
依托单位:
利用CRISPR内源性激活Atoh1转录促进前庭毛细胞再生和功能重建
-
批准号:82371145
-
项目类别:面上项目
-
资助金额:46.00万元
-
批准年份:2023
-
负责人:陶永
-
依托单位:
IL-4协同精氨酸优化种植初期巨噬细胞胞葬作用和成骨微环境的作用及机制研究
-
批准号:82370923
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:张文杰
-
依托单位:
胆固醇合成蛋白CYP51介导线粒体通透性转换诱发Th17/Treg细胞稳态失衡在舍格伦综合征中的作用机制研究
-
批准号:82370976
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:郑凌艳
-
依托单位: